ID: ALA5181774

Max Phase: Preclinical

Molecular Formula: C28H25FN4

Molecular Weight: 436.53

Representations

Canonical SMILES:  CC(C)/N=c1\cc2n(-c3ccccc3)c3ccccc3nc-2cc1NCc1ccc(F)cc1

Standard InChI:  InChI=1S/C28H25FN4/c1-19(2)31-25-17-28-26(16-24(25)30-18-20-12-14-21(29)15-13-20)32-23-10-6-7-11-27(23)33(28)22-8-4-3-5-9-22/h3-17,19,30H,18H2,1-2H3/b31-25+

Standard InChI Key:  IJVNQOMFBWXQES-QCKNELIISA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 436.53

Molecular Weight (Monoisotopic): 436.2063

AlogP: 6.19

#Rotatable Bonds: 5

Polar Surface Area: 42.21

Molecular Species: BASE

HBA: 4

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 8.78

CX LogP: 6.32

CX LogD: 4.93

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.33

Np Likeness Score: -1.05

References

1. Zhang X, Shi Y, Guo Z, Zhao X, Wu J, Cao S, Liu Y, Li Y, Huang W, Wang Y, Liu Q, Li Y, Song D..  (2022)  Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.,  234  [PMID:35279610] [10.1016/j.ejmech.2022.114209]

Source

Source(1):

• Scientific Literature